



AP



7

0300

Dkt. No. 51320-AB/JPW/SHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Graham P. Allaway, et al.
Serial No. : 09/852,238
Filed : May 9, 2001
For : USES OF A CHEMOKINE RECEPTOR FOR
INHIBITING HIV-1 INFECTION

1185 Avenue of the Americas
New York, New York 10036
January 9, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the PTO-1449 form attached hereto as **Exhibit A**. A copy of below listed reference 54 is attached hereto as **Exhibit 1**.

1. U.S. Patent No. 5,440,021, filed February 25, 1994, issued on August 5, 1995, Anan Chuntharapai, et al.;
2. U.S. Patent No. 5,504,003, filed March 8, 1994, issued April 2, 1996, Haodong Li, et al.;
3. Alkhatib, Ghalb, et al., (1996) "CC CKR5: A RANTES, MIP-1 α , MIP-1 β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1", Science 272:1955-1958;
4. Arenzana-Selsdedos, Fernando, et al., (1996) "HIV blocked by chemokine antagonist" Nature 383:400;

Applicants:Graham P. Allaway, et al.

Serial No.:9/852,238

Filed :May 9, 2001

Page 2

5. Bleul, Conrad C., et al., (1996) "The lymphocyte chemoattractant SDF-1 is a ligand for LER/fusion and blocks HIV-1 entry" Nature, 382:829-832;
6. Brenner, T.J., et al., (1991) "Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children", The Lancet, 337:1001-1005;
7. Choe, Hyeryun, et al., (1996), "The β Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates" Cell, 85:1135-1148;
8. Cocchi, Florenza, et al., (1995), "Identification of RANTES, MIP-1 α , and MIP-1 β as the Major HIV-Suppressive Factors provided by CD8+ T cells" Science 270:1811-1815;
9. De Clercq, et al., (1994), "Highly potent and selective inhibition of Human Immunodeficiency virus by the bicyclam derivative JM3100" Antimicrobial Agents and Chemotherapy 38 4:668-674;
10. DeClercq, E., (1995), "Antiviral therapy for human immunodeficiency virus infections", Clinical Microbiology Reviews 8 (2):200-239;
11. Doranz, et al., (1996), "A dual-tropic primary HIV-1 isolate that uses fusin and the β -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusin cofactors", Cell 85:1149-1158;
12. Dragic, T., et al. (1996), "HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5" Nature, 381:667-673;

Applicants:Graham P. Allaway, et al.

Serial No.:9/852,238

Filed :May 9, 2001

Page 3

13. Gong, Jiang-Hong, et al., (1995), "Antagonists of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-terminal Residues", J.Exp.Med., 181:631-640;
14. Gong, Jiang-Hong, et al., (1996), "RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors", The Journal of Biological Chemistry 371:10521-10527;
15. Hattori, T., et al., (1989), "Involvement in tryptase-related cellular protease (s) in human immunodeficiency virus typw 1 infection" FEB 248:48-52;
16. Jones, Simon, A., et al., (1997) "Chemokine Antagonists That Discriminate between Interleukin-8 Receptors", The Journal of Biological Chemistry, 272:16166-16169;
17. Klotman, et al., (1995), "Transgenic models of HIV-1", AIDS, 9(4):313-324;
18. Litwin, et al., (1996), "Human Immunodeficiency virus type 1 membrane fusin mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer", Journal of Virology 70(9):6437-6441;
19. McKnight, Aine, et al., (1997), "Inhibition of Human Immunodeficiency Virus Fusion by a Monoclonal Antibody to a Coreceptor (CXCR4) Is both Cell Type and Virus Strain Dependent" Journal of Virology 71(2):1692-1696.;
20. Moser, Bernhard, et al., (1993), "Interleukin-8 Antagonists Generated by N-terminal Modification", The Journal of Biological Chemistry 268:7125-7128.;

Applicants:Graham P. Allaway, et al.

Serial No.:9/852,238

Filed :May 9, 2001

Page 4

21. Oberlin, Estelle, et al., (1996), "The CXC chemokine SDF-1 is the ligand for LESTR/fusion and prevents infection by t-cell-line-adapted HIV-1", Nature 382:833-835;
22. Raport, Carol, J., et al, (1996), "New members of the chemokine receptor gene family", Journal of Leukocyte Biology 59:18-23;
23. Simmons, Graham, et al., (1997), "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist", Science 267:267-279;
24. Szabo, et al., (1992), "CD4 changes conformation upon ligand binding", The Journal of Immunology , 149(11):3596-3604;
25. Trkola, Alexandra, et al., (1996), "CD4-dependent, antibody-sensitive interaction between HIV-1 and its coreceptor CCR-5", Nature 384:184-187;
26. Wells, Timothy, N.C., et al., (1996), "Selectivity and antagonism of chemokine receptors", Journal of Leukocyte Biology, 59:53-60;
27. Wu, Lijun, et al, (1996) "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5," Nature 384:179-183;
28. Wu, Lijun, et al., (1997), "CCR5 levels and Expression Pattern Correlate With Infectability by Macrophage-tropic HIV-1, In Vitro", J. Exp.Med. 185:1681-1691 ;
29. Zhang, Y.J., et al., (1994)"Structure/Activity Analysis of

Applicants:Graham P. Allaway, et al.

Serial No.:9/852,238

Filed :May 9, 2001

Page 5

Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis", The Journal of Biological Chemistry 269:15918-15924.;

30. Wu, L. et al., 1997, Interaction of Chemokine Receptor CCR5 with its Ligands; Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding, J.Exp.Med., 186(8):1373-1381.;
31. Olson, W.C., 1999, Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5, Journal of Virology 4145-4155.;
31. Mosier, D.E., 1990, Immunodeficient Mice Xenografted with Human Lymphoid Cells: New Modules for in vivo Studies of Human Immunobiology and Infectious Diseases, Journal of Clinical Immunology 10:185-191.;
33. Poignard, P., et al., 1999, Neutralizing Antibodies ave Limited Effects on the Control of Established HIV-1 Infection in Vivo, Immunology, 10:431-438.;
34. Eugen-Olsen, J., et al., 1997, Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T=cell decline in a cohort of HIV-seropositive individuals, AIDS 11:305-310.;
35. Stewart, G.J., et al., 1997, Increased Frequency of CCR-5 Δ 32 heterozygotes among long-term non-progressors with HIV-1 infection, AIDS 11:1833-1838.;
36. Cammack, N., 1999, Human Immunodeficiency virus type 1

Applicants:Graham P. Allaway, et al.

Serial No.:9/852,238

Filed :May 9, 2001

Page 6

- entry and chemokine receptors: a new therapeutic target, Antiviral Chemistry and Chemotherapy, 10:53-62;
37. U.S. Patent No. 5,021,490, issued June 4, 1991 to Murrier et al;
 38. Alkhatib et al., (1997), HIV-1 Coreceptor Activity of CCR5 And Its Inhibition By Chemokines: Independence from G Protein Signaling And Importance of Coreceptor down modulation, Virology 234:340-348;
 39. Berger et al., (1999), Chemokine Receptors as HIV-1 coreceptors: Roles In Viral Entry, Tropism, and Disease, Ann.Rev.Immunol. 17:657-700;
 40. DeClerq, E., et al., (1992), Potent and Selective Inhibition of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By a Class of Bicyclams Interacting With A Virus Uncoating Event, Proc.Natl.Acad.Sci. 89:5286-5290;
 41. Doranz et al., (1997), A Small Molecule Inhibitor Directed Against the Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Coreceptor, J.Exp.Med. 186 (8):1395-1400;
 42. Levy, (1996), Controlling HIV Pathogenesis: The Role of the Noncytotoxic Anti-HIV Response Of CD8+ T Cells. Immunology Today 17:217-224;
 43. Oellerich, M., (1984), Enzyme-Immunoassay: A Review, J. Clin. Chem .Clin.Biochem. 22:(12):895-904;
 44. Samson, M., et al. (1996), Molecular Cloning and Functional Expression Of A New Human CC-chemokine Receptor Gene,

Applicants:Graham P. Allaway, et al.
Serial No.:9/852,238
Filed :May 9, 2001
Page 7

Biochemistry 35: 3362-3367;

45. Scarletti et al., (1997), In Vivo Evolution Of HIV-1 Co-receptor Usage and Sensitivity To Chemokine-mediated Suppression, Natural Medicine 3 (11)L1259-1265;
46. Feng, et al., Science 272:872-877, 10 May 1996;
47. Deng, et al., Nature 381:661-666, 20 June 1996;
48. Dragic, et al., Nature 381:667-673, 20 June 1996;
49. Fahey, et al., Clin Exp. Immunol. 88:1-5, 1992;
50. Fox, J.L., Biol. Technology. 12:128, February 1994;
51. Haynes, et al., Ann. Med. 28:39-41, 1996;
52. Daar, et al., Proc. Natl. Acad. Sci.U.S.A. 87:6574-6478, 1990; and
53. U.S. Patent No. 5,126,433, filed June, 30, 1992, Maddon, et al.
54. International Publication Number WO 79/47319, International Publication Date December 18, 1997, PCT International Application No. PCT/US97/10619, filed June 13, 1997 (Exhibit 1).

The subject application is a continuation application of U.S. Serial No. 09/724,105, filed November 28, 2000, which is a continuation of U.S. Serial No. 08/874,618, filed June 13, 1997. The above listed references 1-29 were submitted and considered

Applicants:Graham P. Allaway, et al.

Serial No.:9/852,238

Filed :May 9, 2001

Page 8

by the United States Patent and Trademark Office in an Information Disclosure Statement filed January 4, 1999 in connection with U.S. Serial No.08/874,618. The above listed references 37-45 were submitted to and considered by the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed

January 19, 2001 in connection with U.S. Serial No. 08/874,618. The above listed references 46-53 were cited in an Office Action issued September 2, 1998 in connection with U.S. Serial No. 08/874,618. The above listed references 30-36 were cited in an Office Action issued November 19, 1999 in connection with U.S. Serial No. 08/874,618. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously cited by, or submitted to, the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120. A copy of the above-listed reference is attached hereto as Exhibit 1.


Summary

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone either of them at the number provided below.


Applicants:Graham P. Allaway, et al.
Serial No.:9/852,238
Filed :May 9, 2001
Page 9

Pursuant to 37 C.F.R. §1.97(b)(3), no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

 1-9-02

John P. White Date
Reg. No. 28,678
Spencer H. Schneider
Reg. No. 45,923

John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

51320-AB/JPW/SHS 09/852,238

Serial No.

09/852,238

Applicants

Graham P. Allaway et al.

Filing Date

May 9, 2001

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US 5 4 4 0 0 2 1	8/5/94	Chuntharapai, et al			
	US 5 5 0 4 0 0 3	4/2/96	H. Li et al.			
	US 5 0 2 1 4 0 9	6/4/91	Murrer et al.			
	US 5 1 2 6 4 3 3	6/30/92	Maddon, et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No
WO 9 7 4 7 3 1 9	12/18/97				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Alkhatib, Ghalb, et al., (1996) "CC CKR5: A RANTES, MIP-1 α , MIP-1 β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1" <i>Science</i> 272:1955-1958;
	Arenzana-Selsdedos, Fernando, et al., (1996) "HIV blocked by chemokine antagonist" <i>Nature</i> 383:400;
	Bleul, Conrad, C., et al., (1996) "The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusion and blocks HIV-1 entry" <i>Nature</i> 382:829-832;
	Brenner, T.J., et al. (1991) "Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children" <i>The Lancet</i> 337:1001-1005;
	Choe, Hyeryun, et al., (1996) "The β -Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates" <i>Cell</i> 85:1135-1148;
	Cocchi, Florenza, et al., (1995) "Identification Of RANTES, MIP-1 α , and MIP-1 β as the Major HIV-Suppressive Factors Produced by CD8 ⁺ T Cells" <i>Science</i> 270: 1811-1815;
	De Clercq, et al., (1994) "Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100" <i>Antimicrobial Agents and Chemotherapy</i> 38(4):668-674;
	De Clercq, E., (1995) "Antiviral therapy for human immunodeficiency virus infections" <i>Clinical Microbiology Reviews</i> 8(2):200-239;
	Doranz, et al., (1996) "A dual-tropic primary HIV-1 isolate that uses fusin and the β -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusin cofactors" <i>Cell</i> 85:1149-1158;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

51320-AB/JPW/SHS

Serial No.

09/852,238

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants

Graham P. Allaway et al.

Filing Date

May 9, 2001

Group

JAN 28 2002

U.S. PATENT DOCUMENTS

Examiner	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Oberlin, Estelle, et al., (1996) "The CXC chemokine SDF-1 is the ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1" <i>Nature</i> 382:833-835;
	Raport, Carol, J., et al., (1996) "New members of the chemokine receptor gene family" <i>Journal of Leukocyte Biology</i> 59:18-23;
	Simmons, Graham, et al., (1997) "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist" <i>Science</i> 276:276-279;
	Szabo, et al., (1992) "CD4 changes conformation upon ligand binding" <i>The Journal of Immunology</i> 149(11):3596-3604;
	Trkola, Alexandra, et al., (1996) "CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5" <i>Nature</i> 384:184-187;
	Wells, Timothy, N.C., et al., (1996) "Selectivity and antagonism of chemokine receptors" <i>Journal of Leukocyte Biology</i> 59:53-60;
	Wu, Lijun, et al., (1996) "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5," <i>Nature</i> 384:179-183;
	Wu, Lijun, et al., (1997) "CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro" <i>J. Exp. Med.</i> 185:1681-1691;
	Zhang, Y.J., et al., (1994) "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis," <i>The Journal of Biological Chemistry</i> 269:15918-15924;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

51320-AB/JPW/SHS

Serial No.

09/852,238

Applicants

Graham P. Allaway et al.


Filing Date

May 9, 2001

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Wu, L. et al., 1997, Interaction of Chemokine Receptor CR% with its Ligands; Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding, <i>J.Exp.Med.</i> 186 (8);1373-1381;
	Olson, W.C., 1999, Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5, <i>Journal of Virology</i> 4145-4155;
	Mosier, D.E., 1990, Immunodeficient Mice Xenografted with Human Lymphoid Cells: New Modules for in vivo Studies of Human Immunobiology and Infectious Diseases, <i>Journal of Clinical Immunobiology</i> 10:185-191;
	Poignard, P. et al., 1999, Neutralizing Antibodies have Limited Effects on the Control of Established HIV-1 Infection in Vivo, <i>Immunobiology</i> 10:431-438;
	Eugen-Olsen, J., et al., 1997, Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T=cell decline in a cohort of HIV-seropositive individuals, <i>AIDS</i> 11:305-310;
	Stewart, G.J., et al., 1997, Increased Frequency of CCR-5 Δ32 heterozygotes among long-term non-progressors with HIV-1 infection, <i>AIDS</i> 11:1833-1838;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

51320-AB/JPW/SHS 09/852,238

Serial No.

Applicants

Graham P. Allaway et al.


Filing Date

May 9, 2001

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Cammack, N., 1999, Human Immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target, <i>Antiviral Chemistry and Chemotherapy</i> , 10:53-62;
	Alkhatib et al., (1997), HIV-1 Coreceptor Activity of CCR5 And Its Inhibition By Chemokines: Independence from G Protein Signaling And Importance of Coreceptor down modulation, <i>Virology</i> 234:340-348;
	Berger et al., (1999), Chemokine Receptors as HIV-1 coreceptors: Roles In Viral Entry, Tropism, and Disease, <i>Ann.Rev.Immunol.</i> 17:657-700;
	DeClerq, E., et al., (1992), Potent and Selective Inhibition of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By a Class of Bicyclams Interacting With A Virus Uncoating Event, <i>Proc.Natl.Acad.Sci.</i> 89:5286-5290;
	Doranz et al., (1997), A Small Molecule Inhibitor Directed Against the Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Coreceptor, <i>J.Exp.Med.</i> 186 (8):1395-1400;
	Levy, (1996), Controlling HIV Pathogenesis: The Role of the Noncytotoxic Anti-HIV Response Of CD8+ T Cells. <i>Immunology Today</i> 17:217-224;
	Oellerich, M., (1984), Enzyme-Immunoassay: A Review, <i>J. Clin. Chem .Clin.Biochem.</i> 22:(12):895-904;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 51320-AB/JPW/SHS		Serial No. 09/852,238			
<div>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</div>				Applicants Graham P. Allaway et al.					
				Filing Date May 9, 2001		Group			
U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number		Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS									
		Document Number		Date	Country	Class	Subclass	Translation	
								Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
		Samson, M., et al. (1996), Molecular Cloning and Functional Expression Of A New Human CC-chemokine Receptor Gene, <i>Biochemistry</i> 35: 3362-3367;							
		Scarletti et al., (1997), In Vivo Evolution Of HIV-1 Co-receptor Usage and Sensitivity To Chemokine-mediated Suppression, <i>Natural Medicine</i> 3 (11)L1259-1265;							
		Feng, et al., <i>Science</i> 272:872-877, 10 May 1996;							
		Deng, et al., <i>Nature</i> 381:661-666, 20 June 1996;							
		Dragic, et al., <i>Nature</i> 381:667-673, 20 June 1996;							
		Fahey, et al., <i>Clin Exp. Immunol.</i> 88:1-5, 1992;							
		Fox, J.L., <i>Biol. Technology</i> , 12:128, February 1994;							
		Haynes, et al., <i>Ann. Med.</i> 28:39-41, 1996;							
		Daar, et al., <i>Proc. Natl. Acad. Sci. U.S.A.</i> 87:6574-6478, 1990.							
EXAMINER				DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									